Efficacy and safety of Ningmitai Capsule in treatment towards type III prostatitis: A randomized, double-blind, placebo-control clinical trial
10.7501/j.issn.0253-2670.2019.10.025
- Author:
Jian-Lin YANG
1
Author Information
1. Department of Urology, Beijing Tongren Hospital, Capital Medical University
- Publication Type:Journal Article
- Keywords:
Clinical evaluation;
NIH chronic prostatitis symptom index (NIH-CPSI);
Ningmitai Capsule;
Placebo;
Type III prostatitis
- From:
Chinese Traditional and Herbal Drugs
2019;50(10):2428-2432
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of Ningmitai Capsule in the treatment towards type III prostatitis. Methods A randomized, double-blind, placebo-control clinical trial was conducted. A total of 50 patients diagnosed as type III prostatitis were divided into two groups with the ratio of 1:1. Patients of the trial group were treated with Ningmitai Capsule at the dose of four grain tid for 4 weeks, and patients of the control group were given placebo in the same way. The efficacy was evaluated by the NIH chronic prostatitis symptom index (NIH-CPSI) while safety-evaluation was evaluated by adverse events, results of urine routine examinations and hepatorenal-function tests. Results:After 4-week treatment, NIH-CPSI total scores were 23.96 ± 1.30 before treatment, and reduced to 16.04 ± 1.66 (P < 0.001). To the contrary, for all these scores, no significant statistical differences exist in placebo-control group. Pain-symptom scores, micturition-symptom scores and QOL scores were all statistically reduced in the trial group. No significant adverse events occurred in all patients who completed the study. Conclusion:Ningmitai Capsule is effective and safe in the treatment of type III prostatitis.
